In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—

Drug Development Lessons for 2026 Drawn from 2025 Realities, Upcoming Webinar Hosted by Xtalks

2026/02/18 21:46
3 min read

In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—and what quietly stalled. The featured speakers will share insights into smart AI adoption, including how to scale innovation with confidence, not chaos. The speakers will also discuss sponsor-CRO partnership dynamics, involving what changed in 2025, where friction shows up, and how high-performing teams clarify roles, decisions, and accountability early. Attendees will learn how leaders navigate shifting priorities, resourcing, and assumptions without compromising timelines or quality. The speakers will also share when connected partners accelerate outcomes—and when handoffs, systems, and workflows introduce avoidable drag. Attendees can expect candid lessons, real trade-offs, and a few myths challenged.

TORONTO, Feb. 18, 2026 /PRNewswire/ — Over the past year, “progress” in drug development started to look very different. AI moved beyond pilots into day-to-day execution, while protocols, regulatory expectations, and budgets grew more complex. The mandate to accelerate only intensified—and so did the pressure on sponsor-CRO partnerships to deliver with clarity and confidence.

So what actually worked in 2025—and what didn’t?

Join an executive fireside chat with leaders from Thermo Fisher Scientific and the PPD™ clinical research business of Thermo Fisher Scientific for a candid, lessons-learned conversation grounded in real-world delivery. Hear what teams discovered in execution — not theory — and how those insights are shaping 2026 plans in an environment where uncertainty is the new baseline.

You’ll walk away with practical takeaways on:

  • Where AI and digital workflows delivered real impact, where adoption stalled, and how to scale responsibly
  • How CRO partnership dynamics changed—what’s driving friction, what “good” looks like now, and how to reset ways of working
  • How to navigate shifting priorities and constraints without compromising timelines or quality
  • How to reduce integration pitfalls across systems, vendors, and workflows to build a more resilient operating model

Bring your questions and join the conversation live. Register now to turn 2025 learnings into smarter, faster, more confident decisions for 2026.

Join Krishna Cheriath, Vice President, Head of Digital and AI, BioPharma Services, Thermo Fisher Scientific; Mike Kleppinger, President, Commercial Operations, the PPD clinical research business of Thermo Fisher Scientific; Brenda Bruker, Executive Director, Clinical Development Strategy & Innovation, Clinical Research Group, Thermo Fisher Scientific; and Guzel Adams (Moderator), Customer Insights & Strategy Director, the PPD clinical research business of Thermo Fisher Scientific, for the live webinar on Tuesday, March 10, 2026, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit Drug Development Lessons for 2026 Drawn from 2025 Realities.

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Media Contact: Vera Kovacevic Tel: +1 (416) 977-6555 x371 Email: [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/drug-development-lessons-for-2026-drawn-from-2025-realities-upcoming-webinar-hosted-by-xtalks-302691171.html

SOURCE Xtalks

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0.07923
$0.07923$0.07923
-0.50%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

World Order Shift Sparks New Crypto Cycle, Analyst Predicts

World Order Shift Sparks New Crypto Cycle, Analyst Predicts

A fraying global order and a renewed bid for gold may be the early setup for the next crypto cycle, even if Bitcoin hasn’t confirmed the signal yet. That’s the
Share
NewsBTC2026/02/18 22:00
A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release

A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release

The post A Netflix ‘KPop Demon Hunters’ Short Film Has Been Rated For Release appeared on BitcoinEthereumNews.com. KPop Demon Hunters Netflix Everyone has wondered what may be the next step for KPop Demon Hunters as an IP, given its record-breaking success on Netflix. Now, the answer may be something exactly no one predicted. According to a new filing with the MPA, something called Debut: A KPop Demon Hunters Story has been rated PG by the ratings body. It’s listed alongside some other films, and this is obviously something that has not been publicly announced. A short film could be well, very short, a few minutes, and likely no more than ten. Even that might be pushing it. Using say, Pixar shorts as a reference, most are between 4 and 8 minutes. The original movie is an hour and 36 minutes. The “Debut” in the title indicates some sort of flashback, perhaps to when HUNTR/X first arrived on the scene before they blew up. Previously, director Maggie Kang has commented about how there were more backstory components that were supposed to be in the film that were cut, but hinted those could be explored in a sequel. But perhaps some may be put into a short here. I very much doubt those scenes were fully produced and simply cut, but perhaps they were finished up for this short film here. When would Debut: KPop Demon Hunters theoretically arrive? I’m not sure the other films on the list are much help. Dead of Winter is out in less than two weeks. Mother Mary does not have a release date. Ne Zha 2 came out earlier this year. I’ve only seen news stories saying The Perfect Gamble was supposed to come out in Q1 2025, but I’ve seen no evidence that it actually has. KPop Demon Hunters Netflix It could be sooner rather than later as Netflix looks to capitalize…
Share
BitcoinEthereumNews2025/09/18 02:23
XRP’s 13-Year Ascending Channel Targets $18, Crypto Analyst Says

XRP’s 13-Year Ascending Channel Targets $18, Crypto Analyst Says

XRP continues to respect a multi-year ascending channel that has been intact for more than a decade. The analysis from Dark Defender suggests that if this structure
Share
Ethnews2026/02/18 22:35